Hims & Hers stock price has imploded this year, erasing some of the gains made in 2024 when it became one of the ...

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

In the US, ad spending on X declined by 2 per cent in the first two months of 2025 compared with the previous year, even as firms like Hulu and Unilever cautiously returned to the platform. American ...

Investors became excited about the prospects of the company, while its Super Bowl ad and the acquisition ... Drug Administration's shortage list. Hims & Hers has been selling semaglutide-based ...

Hims & Hers turned in tremendous revenue and profitability ... Investors became excited about the prospects of the company, while its Super Bowl ad and the acquisition of an at-home lab facility ...

Hims & Hers had just over 1,600 employees at the end ... In February, it ran a Super Bowl ad that promoted its compounded weight loss medications. But the ad drew bipartisan criticisms from ...

Hims & Hers (NYSE:HIMS) — the hypergrowth telehealth ... An example of its marketing success would be the recent Superbowl ad campaign, which reverberated through the entire healthcare industry.

Musk and X chief executive Linda Yaccarino have set a goal that aims to boost advertising revenues back to 2022 levels, ...